The ongoing ALLTogether1 trial (NCT04307576) also treats all patients with ABL-class ALL with non-random experimental intervention, with the addition of imatinib from the induction phase for patients < 25 years and from the consolidation phase for patients ≥ 25 years, with the aim to reduce the risk of disease recurrence. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.